HuMab-216 (Stanford University)

N/A

Report date: 2022/08/29 20:00:24

Base Information

Drug NameHuMab-216 (Stanford University)
Drug Alias NamemAb-216Human monoclonal antibody 216 (Stanford University)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionUpdating
TargetsNot applicable
Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, LymphoidLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesStanford University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institutes Of HealthStanford University
Active IndicationsN/A
Inactive IndicationsPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, LymphoidLeukemia

Other Information

ATC CodeN/A
Related LinksN/A